A 20-cent 'wonder drug' is being studied as a colon cancer-stopping supplement, and it looks promising
Scientists have noticed that people who take it may also get some colon cancer prevention benefits.
Early research gives hints about how it might be used to help in colon cancer treatment.
A cheap, widely-prescribed diabetes drug that some doctors have called a "wonder drug" may hold promise as a colon-cancer-stopping supplement.
Scientists who presented at the American Association for Cancer Research conference in Chicago last week are studying how metformin — the most popular diabetes medication worldwide — interacts with tough-to-treat colon cancer cells. Their research is still early and ongoing.
"Metformin seems like it could have a really interesting supplemental approach to therapy," Holli Loomans-Kropp, a gastrointestinal cancer prevention researcher at The Ohio State University, who is leading the ongoing study, told Business Insider. "We're opening up some doors to what this could do."
Previous research has highlighted how people taking metformin for diabetes have lower colon cancer rates, suggesting the drug may be doing something protective to help prevent cancer from developing. This new study is one of the first to look at whether metformin can actually fight back against colon cancer cells once the disease develops.
Based on what Loomans-Kropp and her team have seen so far in cell culture dishes, metformin looks like it could become a helpful "supplement" to certain cancer treatment regimens in the future. It wouldn't be potent enough to treat cancer on its own, but could be used alongside other treatments.
She is especially excited about what it might do for a common type of colon cancer with a mutated KRAS gene, which tends to be very tough to treat. Her work, if successful, would require additional positive results in animals and then in people to become a prescription that oncologists can reliably use in the clinic.
A drug that changes how the body uses energy
Metformin stimulates a key cellular cleanup process called autophagy. Exercise can also induce autophagy, but in a slightly different way.One of the big benefits Loomans-Kropp sees to studying metformin for colon cancer treatment is a practical one — it's a drug that's already widely accessible and affordable.
"I always like to ask the question: are there medications or agents that we already know, that are already used, that we have safety/toxicity profiles for, that we can then repurpose for something else?"
Metformin has been studied and used by millions of patients worldwide. And it's cheap — an off-patent, generic drug that costs about 10 to 20 cents per pill.
It's sometimes referred to as a "wonder drug" by doctors for the beneficial effects it may have on patients who take it, beyond blood sugar control. Scientists have studied it for heart health, cancer prevention, and dementia.
Metformin works for diabetes because it changes the way the body processes and produces sugar. Some scientists suspect it may hold promise for improving aging for a similar reason: because it regulates how the body uses energy, and encourages more self-eating (autophagy), much like exercise or fasting. Perhaps metformin could also inhibit the ways that colon cancer finds energy to grow and develop.
"If metformin maybe can be used to redirect or change how the cell uses energy, which then ultimately changes how it divides and how it proliferates, this could be a mechanism to exploit," Loomans-Kropp said.
It's this same energy-shifting mechanism that has longevity researchers excited about metformin as a tool for disease prevention.
Dr. Nir Barzilai, a leading longevity researcher who suspects metformin may be beneficial for healthy aging, says he thinks metformin may be a "suitable" option for cancer prevention. When it comes to fighting cancer, he agrees with Loomans-Kropp that more study is needed.
"Let the science lead," he told Business Insider in an email.
Loomans-Kropp is hoping that if these initial cancer cell results are successful, she can begin testing metformin as colon cancer treatment on animals within a year.
Read the original article on Business Insider
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Axios
3 hours ago
- Axios
Off-the-shelf vaccine shows success against deadly cancers
An experimental vaccine targeting one of the most common genetic drivers of hard-to-treat pancreatic and colorectal cancers prevented their recurrence, raising hopes for an "off the shelf" treatment that can train the immune system to attack malignancies. Why it matters: If shown effective in further trials, the vaccine could become a particularly important tool in staving off the return of pancreatic cancer, which sees roughly 80% of surgically removed tumors recur within five years. What they're saying:"This was a trial all of us in the medical oncology world have been waiting for," said Tracy Proverbs-Singh, an oncologist at Hackensack Meridian's John Theurer Cancer Center. "We see these patients for five years, we see the recurrences, we have to re-treat them, and it's devastating. And after we finish chemo, there's not a lot we can do." Go deeper: The peptide vaccine targets the KRAS mutation that occurs in roughly 90% of pancreatic cancers and half of colorectal cancers. Researchers administered the shot, called ELI-002 2P, to 25 patients who'd received conventional treatments but still had small amounts of cancer left in their bodies and were at high risk of relapse. Half of patients had no relapse by 16.3 months, and median overall survival was 28.9 months — both exceeding historical norms, per the study in Nature Medicine. The greatest benefit was seen in patients who had strong T cell responses. At the 20-month mark, 17 of the 25 patients had strong immune responses with 11 of those patients having no recurrence and six having delayed recurrence. The latter successfully underwent further treatment. "All the 17 were still alive which is why we think there's optimistically, something real going on here, because that's much better than what we might have expected historically," said Zev Wainberg, co-director of the UCLA GI Oncology Program and one of the lead authors. Yes, but: Researchers do not yet understand why eight of the 23 patients did not develop a strong immune response as a result of the vaccine. Between the lines: Much of the enthusiasm around therapeutic cancer vaccines has centered on personalized mRNA technology. It is notable that researchers were able to use a non-personalized vaccine because it can be more easily developed at scale. "It's a big shot in the arm for the pancreatic cancer vaccine, which has been elusive in the context of us being able to get something that's effective in the early stages," said Madappa Kundranda, division chief for cancer medicine at Banner MD Anderson Cancer Center. Reality check: This is still a small Phase 1 trial and will require a more robust randomized controlled trial. Wainberg said the team has already completed such a trial and should have results back in 2026. What to watch: Pancreatic cancer, which has a five-year survival rate of around 13% in the U.S., could be treated very differently within the next two years as multiple new drugs targeting the same mutations are also developed.
Vox
18 hours ago
- Vox
Rudolph and all of the other reindeer are probably dying from climate change
is an environmental correspondent at Vox, covering biodiversity loss and climate change. Before joining Vox, he was a senior energy reporter at Business Insider. Benji previously worked as a wildlife researcher. It's bad enough that climate change is ruining the dream of a white Christmas for many people, as warming makes snow in some regions less likely. Now, apparently, it's coming for reindeer, too. Reindeer aren't just creatures of Christmas myth; they're real animals — a kind of deer that live in the Arctic, from northern Europe and Russia to North America, where they're commonly known as caribou. These animals are remarkably adapted to cold weather, sporting thick fur, a snout that warms the air they take in, and uniquely structured hooves that help them shovel snow to find food, such as lichen. But they've also survived bouts of Arctic warming that occurred thousands of years ago, thanks to their ability to travel long distances in search of colder habitats. These adaptations are, however, no match for modern climate change. The Arctic is warming quickly from a higher baseline temperature compared to natural fluctuations in the distant past. Wild reindeer search for food under the midnight sun on the Svalbard archipelago in the Arctic Circle. Ben Birchall/PA Wire Over the last few decades, wild Arctic reindeer populations have declined by about two-thirds, from 5.5 million to around 1.9 million, largely due to warming, according to previous research. Rising temperatures can affect reindeer health directly — causing the animals to overheat and get sick — and indirectly by limiting their supply of food. Now, it's clear those declines will likely continue. A new study in the journal Science Advances found that if the world doesn't quickly rein in greenhouse gas emissions, the global wild reindeer population could plummet by nearly 60 percent by the end of the century. Those declines will be far more severe in North America, where they could exceed 80 percent, according to the study's models, which reconstructed 21,000 years of reindeer population data using fossil records, DNA, and other data sources. That's because North America is expected to lose more habitat that can support reindeer to warming than elsewhere, said Damien Fordham, a study author and researcher at the University of Adelaide. Even under a more modest emissions scenario — in which countries cut back what they spew into the atmosphere — the study projects steep population declines. You can see these results in the chart below, which shows projected declines based on a high and moderate emissions scenario, respectively. 'These results are absolutely concerning,' said Jennifer Watts — Arctic program director at the Woodwell Climate Research Center, a nonprofit research organization — who was not involved in the new study. 'Given how quickly and severely the Arctic is warming at present, the results from this study are not overly surprising, and should serve as yet another wake-up call for humans to curtail anthropogenic drivers of climate warming.' The study offers yet another example of how climate change is threatening biodiversity and how those threats in turn affect humans. Reindeer are not only a critical food source for some Arctic Indigenous communities — like Alaskan Natives and the Inuit people of North America — but also a cornerstone of their culture, similar to salmon or wolves for some tribal nations in other parts of the US. If major polluting nations, like the US, China, and India don't curtail their emissions, it could further endanger the food sovereignty of those communities. Beyond their direct impact on human well-being, reindeer also shape the tundra ecosystems — quite literally making them what they are — by limiting the growth of trees and shrubs, spreading seeds, and fertilizing the soil. 'We should care about the fate of reindeer and caribou with the same concern we give to the fate of polar bears and other Arctic animals,' Watts told Vox. 'The well-being of entire ecosystems and humans living across the Arctic depend on their survival.'
Forbes
a day ago
- Forbes
An Unexpected Clue To How Metformin, The World's Top Diabetes Drug, Works
Metformin is an unassuming hero of modern medicine. For more than sixty years, this humble pill has been a mainstay of diabetes care, helping millions of people manage their blood sugar. It lowers blood sugar, improves cholesterol, modestly reduces weight, and is so safe it's prescribed to millions worldwide. And yet, for decades, scientists haven't fully understood how it works. The standard explanation has long been that metformin works in the liver, reducing how much sugar it sends into the bloodstream. It also helps muscles and fat cells respond more effectively to insulin. More recent research added other suspects: the gut, which can tweak hormones and the microbiome, and a cellular pathway called mTOR, a major regulator of metabolism and longevity. But a new study published in Science Advances suggests that part of metformin's magic might be happening somewhere unexpected: in the brain. The Blood Sugar Command Center Researchers turned their attention to a protein called Rap1, found in a small pocket of the brain known as the ventromedial hypothalamus (VMH). This area is a metabolic mission control, coordinating hunger, energy use, and glucose balance. When scientists switched off Rap1 in this brain region in mice, blood sugar levels fell, even without metformin. But when they kept Rap1 switched on, metformin lost its blood-sugar-lowering power. The results hint that, at the doses typically prescribed, metformin may partly work by silencing Rap1's activity in the brain, not just by acting on the liver or gut. Most of us think of blood sugar control as the domain of the pancreas, liver, and muscles. Yet the brain is deeply involved. The VMH works like an air traffic controller, taking in information from across the body and sending out signals to adjust glucose production and use. Metformin, it seems, may be tapping into this high-level control system. By dialing down Rap1 activity, the drug might trigger a cascade of neural instructions that ripple out to the rest of the body, improving how tissues handle sugar. Beyond Diabetes Metformin has drawn attention far beyond the diabetes world. It's being studied for its potential to slow certain aspects of aging, with researchers probing whether its effects on pathways like mTOR could help extend not just lifespan but healthspan. The discovery of the brain-Rap1 link opens new possibilities. Could this same circuit be part of metformin's longevity effects? If so, drugs that target Rap1 or its related pathways might someday offer more precise ways to improve metabolism or promote healthy aging, perhaps without some of metformin's side effects. When Old Drugs Tell New Tales This does not mean discarding what is already known about metformin's effects on the liver, muscles, and gut. Those mechanisms are still in play. But at everyday doses, the brain may have a starring role in how the drug works. At much higher doses, peripheral mechanisms can take over, but in real-world clinical use, the brain's contribution could be key. The finding is also a reminder that the brain and body are not separate actors in the story of metabolism. They are in constant conversation, adjusting and responding to keep systems in balance. And as this research shows, an old drug can reveal something entirely new about that conversation. Even after six decades, metformin still has secrets to share: secrets that may change how both the medicine itself and the intricate links between the brain, the body, and health are understood.
